Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
61 hedge funds and large institutions have $33.5M invested in Adamas Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 25 reducing their positions, and 23 closing their positions.
128% more call options, than puts
Call options by funds: $66K | Put options by funds: $29K
16% less funds holding
Funds holding: 73 → 61 (-12)
25% less capital invested
Capital invested by funds: $44.8M → $33.5M (-$11.3M)
44% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 25
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.82M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.21M |
| 3 |
Renaissance Technologies
New York
|
+$1.36M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$598K |
| 5 |
Jane Street
New York
|
+$403K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$5.2M |
| 2 |
BlackRock
New York
|
-$3.47M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.19M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.15M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$661K |
ADMS Hedge Fund Activity: Q2 2020 in Review
61 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2020, worth a combined $33.5M — down 25% from $44.8M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ADMS and 11 opened new positions — a net loss of 12 holders — while 25 trimmed existing stakes and 14 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $2.82M. The largest seller was Macquarie Group, exiting entirely with an estimated $5.2M sold.
- 61 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2020, down from 73 in Q1 2020.
- Funds reported $33.5M of Adamas Pharmaceuticals stock for Q2 2020, down 25% quarter-over-quarter.
- 11 funds opened new Adamas Pharmaceuticals positions in Q2 2020 and 23 closed out, a net change of -12 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2020 was Opaleye Management, an estimated $2.82M added.
- The largest Adamas Pharmaceuticals seller in Q2 2020 was Macquarie Group, an estimated $5.2M sold.
Based on aggregated 13F filings for Q2 2020.